Skip to megamenu (after main content)
Meet us next:   BIO International Convention 2025 – 4 September  ●  ELRIG – Drug Discovery in Scotland 2025 – 17 September  ●  The Cell & Gene Meeting on the Mesa 2025 – 6-8 October (in person) & 9-10 October (virtual)  ●  ELRIG – Drug Discovery – 21-22 October  ●  more on our events calendar
Prices for NutriStem, NutriCoat, and NutriFreez products will increase effective 1st August. Lock in the current price by getting your order by 31st July.

Recombinant human FGF-9 protein

QK039

Brand: Qkine

Human FGF-9 protein is a member of the fibroblast growth factor (FGF) family, FGF-9 is involved in many developmental processes including neural and skeletal development. Recombinant FGF-9 is used frequently in the generation of kidney organoids.

Qkine recombinant human FGF-9 is a highly pure and bioactive 23 kDa protein, animal origin-free (AOF) and carrier-protein free (CF).

Currency: 

Product name Catalog number Pack size Price Price (USD) Price (GBP) Price (EUR)
Recombinant human/mouse/rat follistatin-resistant activin A (FRACTA) protein, 25 µg QK035-0025 25 µg (select above) $ 280.00 £ 205.00 € 240.00
Recombinant human/mouse/rat follistatin-resistant activin A (FRACTA) protein, 50 µg QK035-0050 50 µg (select above) $ 410.00 £ 305.00 € 357.00
Recombinant human/mouse/rat follistatin-resistant activin A (FRACTA) protein, 100 µg QK035-0100 100 µg (select above) $ 620.00 £ 455.00 € 532.00
Recombinant human/mouse/rat follistatin-resistant activin A (FRACTA) protein, 500 µg QK035-0500 500 µg (select above) $ 2,500.00 £ 1,840.00 € 2,150.00
Recombinant human/mouse/rat follistatin-resistant activin A (FRACTA) protein, 1000 µg QK035-1000 1000 µg (select above) $ 3,950.00 £ 2,900.00 € 3,388.00

Note: prices shown do not include shipping and handling charges.

Qkine company name and logo are the property of Qkine Ltd. UK.

Alternative protein names
Fibroblast growth factor 9, FGF-9, Glia-activating factor, GAF, Heparin-binding growth factor 9, HBGF-9
Species reactivity

human

species similarity:
mouse – 99%
rat – 99%
bovine – 98%
porcine – 98%

Alternative(s)

Summary

  • High purity optimized human FGF-9 protein (Uniprot: P31371)
  • 23 kDa (monomer)
  • >98%, by SDS-PAGE quantitative densitometry
  • Expressed in E. coli
  • Animal origin-free (AOF) and carrier protein-free
  • Manufactured in Qkine's Cambridge, UK laboratories
  • Lyophilized from HEPES, NaCl
  • Resuspend in sterile-filtered water at >50 µg/ml, add carrier protein if desired, prepare single use aliquots and store frozen at -20 °C (short-term) or -80 °C (long-term).
Handling and Storage FAQ

Featured applications

  • Kidney organoid generation
  • Chemically defined media

Bioactivity

FGF-9 activity is determined using the Promega serum response element luciferase reporter assay (*)  in transfected HEK293T cells. Cells are treated in triplicate with a serial dilution of FGF-9 for 3 hours. Firefly luciferase activity is measured and normalized to the control Renilla luciferase activity. EC50 = 246.2 pM (5.7 ng/mL). Data from Qk039 lot #104295. *Promega pGL4.33[luc2P/SRE/Hygro] #E1340

Qk039-FGF-9-bioactivity

Purity

FGF-9 protein migrates as a single band at 23 kDa in non-reducing (NR) conditions and upon reduction (R). No contaminating protein bands are visible. Purified recombinant protein (3 µg) was resolved using 15% w/v SDS-PAGE in reduced (+β-mercaptothanol, R) and non-reduced (NR) conditions and stained with Coomassie Brilliant Blue R250. Data from Qk039 lot #104295

human-FGF-9-Qk039-protein-purity-lot-04295

Further quality assays

  • Mass spectrometry: single species with expected mass
  • Analytical reversed-phase: single sharp peak
  • Endotoxin: <0.005 EU/μg protein (below level of detection)
  • Recovery from stock vial:  >95%

Qk039_FGF-9_Peprotech-comparison

Quantitative luciferase assay with Qkine FGF-9 (Qk039, green) and alternative supplier FGF-9 (Supplier B, black). Cells were treated in triplicate with a serial dilution of FGF-9 for 3 hours. Firefly luciferase activity was measured and normalized to control Renilla luciferase activity.


Protein background

Part of thefibroblast growth factor(FGF) family, FGF-9 is a growth factor that has been implicated in many developmental processes, including in lung [1] and skeletal [2] development, sex determination [3], and neural patterning in the optic neuroepithelium [4]. Also known as glia-activating factor, FGF-9 also modulates the development and survival of neurons and glia and has been reported to play pro-survival roles (enhances cell proliferation, and alleviating cell death) in neurodegenerative diseases, such as Parkinson’s disease, Huntington’s Disease and Alzheimer’s disease [5]. FGF-9 protein is commonly used in the generation of kidneyorganoids[6].

FGF-9 protein binds and activates the ‘c’ splice isoform of FGF receptor 1–3 [7], and can activate a number of signalling pathways, such as ERK, STAT, PI3K and MAP kinase pathways.

Background references

  1. Yin, Y., Wang, F. & Ornitz, D. M. Mesothelial- and epithelial-derived FGF9 have distinct functions in the regulation of lung development. Development 138, 3169–3177 (2011).doi: 10.1242/dev.065110
  2. Hung, I. H., Schoenwolf, G. C., Lewandoski, M. & Ornitz, D. M. A combined series of Fgf9 and Fgf18 mutant alleles identifies unique and redundant roles in skeletal development. Dev Biol 411, 72–84 (2016).doi: 10.1016/j.ydbio.2016.01.008
  3. Schmahl, J., Kim, Y., Colvin, J. S., Ornitz, D. M. & Capel, B. Fgf9 induces proliferation and nuclear localization of FGFR2 in Sertoli precursors during male sex determination. Development 131, 3627–3636 (2004).doi: 10.1242/dev.01239
  4. Zhao, S. et al. Patterning the optic neuroepithelium by FGF signaling and Ras activation. Development 128, 5051–5060 (2001).doi.org/10.1242/dev.128.24.5051
  5. Yusuf, I. O. et al. Fibroblast Growth Factor 9 Suppresses Striatal Cell Death Dominantly Through ERK Signaling in Huntington’s Disease. Cell Physiol Biochem 48, 605–617 (2018).doi: 10.1159/000491889
  6. Morizane, R. & Bonventre, J. V. Kidney Organoids: A Translational Journey. Trends in Molecular Medicine 23, 246–263 (2017).doi: 10.1016/j.molmed.2017.01.001
  7. Liu, Y. et al. Regulation of Receptor Binding Specificity of FGF9 by an Autoinhibitory Homodimerization. Structure 25, 1325-1336.e3 (2017).doi: 10.1016/j.str.2017.06.016